Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO | 630.2k | -- | 1957 |
| Mr. Richard Clavano Narido | Treasurer | 255.01k | -- | 1978 |
| Mr. Michael S. Abrams | Chief Financial Officer | -- | -- | 1970 |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer | 240k | -- | 1962 |
| Suzanne Messere | Investor Relations | -- | -- | -- |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist | -- | -- | 1947 |
| Mr. Matthew Patrick Duffy | Chief Business Officer & Co-CEO of Hope Therapeutics | -- | -- | 1963 |
NRx Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available